Depression Treatment Denied by Insurance? A Complete Appeal Guide

Major depressive disorder affects more than 21 million American adults each year, and treatment often requires a sequential approach — trying multiple medications, adding augmentation strategies, and in some cases accessing advanced treatments like TMS or ECT. At each step of this process, insurance companies create barriers through step therapy requirements, Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization, and coverage denials. Here is how to fight back at every stage of depression treatment.

Stage 1: Antidepressant Medication Denials

Step therapy for antidepressants. Most insurers require that patients try one or more generic antidepressants before approving brand-name medications or newer agents. Step therapy for depression medication is common and sometimes appropriate — but it becomes a Mental Health Parity Act (MHPAEA) Explained" class="auto-link">MHPAEA concern when:

• The step therapy requirements for psychiatric medications are more burdensome than step therapy for comparable chronic disease medications (e.g., antihypertensives, lipid-lowering agents)
• The required prior medications are clinically inappropriate for the specific patient (e.g., requiring an SSRI despite documented SSRI intolerance or a contraindication)
• The insurer requires a longer trial period than is supported by clinical evidence

Exceptions to step therapy. Most plans allow step therapy exceptions when a patient has already tried the required medications, when a contraindication exists, or when the prescribing physician documents clinical reasons the required medication is inappropriate. Request the plan's step therapy exception process and document the clinical rationale for the exception thoroughly.

Stage 2: Augmentation Strategy Denials

When initial antidepressants fail, psychiatrists often augment with second agents — atypical antipsychotics (aripiprazole, quetiapine, olanzapine, brexpiprazole), lithium, thyroid hormone, or buspirone. These augmentation agents frequently require prior authorization, and denials follow several patterns:

"Not first-line treatment." Prior authorization for augmentation agents is often denied because the insurer's criteria require failure of multiple additional medications before approving augmentation. Cite the treating psychiatrist's documented rationale for augmentation, the clinical evidence for the specific augmentation strategy, and any MHPAEA comparison to comparable augmentation approaches for medical chronic disease management.

Brand-only augmentation agent denials. Some atypical antipsychotics used for depression augmentation are available only as brand-name drugs. Denials based on no-generic availability should be challenged with clinical documentation that the branded agent is medically appropriate and that no adequate generic alternative exists.

Stage 3: Advanced Treatment Denials (TMS and ECT)

When multiple antidepressants and augmentation strategies have failed, psychiatrists may recommend TMS or ECT. These advanced treatments have their own denial patterns — covered in dedicated guides on this site — but the key principle at this stage is:

Document a comprehensive treatment failure history. Every prior medication, dose, duration, and outcome must be documented. This treatment history is the foundation of any advanced treatment authorization request.

The definition of treatment-resistant depression. TRD is generally defined as failure of at least two adequate antidepressant trials. "Adequate" means sufficient dose for sufficient duration (typically 6-8 weeks). Your appeal must document that prior trials met this threshold.

MHPAEA Throughout the Depression Treatment Journey

MHPAEA applies at every stage of depression treatment:

• Antidepressant step therapy must be compared to step therapy for comparable chronic medical medications.
• Augmentation PA requirements must be compared to comparable medical chronic disease management strategies.
• TMS and ECT prior authorization criteria must be compared to comparable interventional medical procedures.
• Therapy session limits for depression treatment must be compared to session limits for comparable medical rehabilitation.

Request the MHPAEA comparative analysis whenever you encounter a denial at any stage. Accumulating evidence of parity violations across the treatment journey is a powerful regulatory complaint basis.

Documenting Depression Severity

Insurance denials often characterize depression as mild or moderate to justify lower-intensity or lower-cost treatment. Counter this with:

• PHQ-9 scores (moderate: 10-14; moderately severe: 15-19; severe: 20-27)
• Treating psychiatrist's clinical assessment of functional impairment
• Documentation of suicidal ideation, inability to function, or failed prior treatment
• Physical health complications of untreated depression

Building Your Depression Treatment Appeal

Include:

• Treating psychiatrist's comprehensive letter documenting diagnosis, severity, treatment history, and medical necessity
• PHQ-9 or other validated severity scores
• Medication trial history (for step therapy or TRD-related denials)
• Clinical guideline citations (APA Practice Guidelines for Major Depressive Disorder)
• MHPAEA comparison for the specific type of denial
• Step therapy exception documentation if applicable

Fight Back With ClaimBack

Depression treatment denials occur at every level of care — from first-line medication to ECT. ClaimBack helps you build a targeted appeal for wherever in the treatment journey you are facing a barrier.

Start your depression treatment appeal at ClaimBack and get the care you need.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: Which Should You File?